Jieying Yang

1.0k total citations
11 papers, 318 citations indexed

About

Jieying Yang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jieying Yang has authored 11 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Jieying Yang's work include Circular RNAs in diseases (3 papers), Cancer-related molecular mechanisms research (3 papers) and RNA modifications and cancer (2 papers). Jieying Yang is often cited by papers focused on Circular RNAs in diseases (3 papers), Cancer-related molecular mechanisms research (3 papers) and RNA modifications and cancer (2 papers). Jieying Yang collaborates with scholars based in China. Jieying Yang's co-authors include Yi Zhang, Wei Li, Mengjia Song, Jian‐Chuan Xia, Desheng Weng, Qiuzhong Pan, Chaopin Yang, Junyi He, Yue Huang and Yulong Han and has published in prestigious journals such as British Journal of Cancer, Frontiers in Immunology and Gene.

In The Last Decade

Jieying Yang

11 papers receiving 317 citations

Peers

Jieying Yang
He Tian China
Jieying Yang
Citations per year, relative to Jieying Yang Jieying Yang (= 1×) peers He Tian

Countries citing papers authored by Jieying Yang

Since Specialization
Citations

This map shows the geographic impact of Jieying Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieying Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieying Yang more than expected).

Fields of papers citing papers by Jieying Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jieying Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieying Yang. The network helps show where Jieying Yang may publish in the future.

Co-authorship network of co-authors of Jieying Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jieying Yang. A scholar is included among the top collaborators of Jieying Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jieying Yang. Jieying Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Song, Mengjia, Jieying Yang, Qiuzhong Pan, et al.. (2023). Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer. Theranostics. 13(5). 1649–1668. 12 indexed citations
2.
Yang, Jieying, Zhixing Guo, Mengjia Song, et al.. (2023). Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma. Frontiers in Immunology. 14. 1212577–1212577. 13 indexed citations
3.
Huang, Yue, Jieying Yang, Qiuzhong Pan, et al.. (2022). CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. Cell Death and Disease. 13(3). 251–251. 35 indexed citations
4.
Yang, Jieying, Mengjia Song, Qiuzhong Pan, et al.. (2022). SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway. International Journal of Biological Sciences. 18(14). 5241–5259. 23 indexed citations
5.
Song, Mengjia, Ziqi Zhou, Jianxiong Zeng, et al.. (2021). Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker. Oncology Letters. 21(3). 205–205. 12 indexed citations
6.
Song, Mengjia, Qiuzhong Pan, Jieying Yang, et al.. (2020). Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma. British Journal of Cancer. 123(10). 1521–1534. 62 indexed citations
7.
Pan, Qiuzhong, Jingjing Zhao, Chaopin Yang, et al.. (2020). Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. OncoImmunology. 9(1). 1752563–1752563. 14 indexed citations
8.
Song, Mengjia, Jieying Yang, Junyi He, et al.. (2019). Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging. 11(22). 10422–10453. 26 indexed citations
9.
Li, Wei, et al.. (2018). MicroRNA-20a protects human aortic endothelial cells from Ox-LDL-induced inflammation through targeting TLR4 and TXNIP signaling. Biomedicine & Pharmacotherapy. 103. 191–197. 58 indexed citations
10.
Zhang, Yi, et al.. (2018). MicroRNA-145 alleviates high glucose-induced proliferation and migration of vascular smooth muscle cells through targeting ROCK1. Biomedicine & Pharmacotherapy. 99. 81–86. 29 indexed citations
11.
Yang, Jieying, Jin-Jie Xu, Yanhong Ni, et al.. (2018). SIRT1 knock-in mice preserve ovarian reserve resembling caloric restriction. Gene. 686. 194–202. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026